HomeCompareCERC vs JNJ

CERC vs JNJ: Dividend Comparison 2026

CERC yields 68.26% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CERC wins by $948.9K in total portfolio value
10 years
CERC
CERC
● Live price
68.26%
Share price
$2.93
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$968.9K
Annual income
$249,593.79
Full CERC calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — CERC vs JNJ

📍 CERC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCERCJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CERC + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CERC pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CERC
Annual income on $10K today (after 15% tax)
$5,802.05/yr
After 10yr DRIP, annual income (after tax)
$212,154.72/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, CERC beats the other by $211,451.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CERC + JNJ for your $10,000?

CERC: 50%JNJ: 50%
100% JNJ50/50100% CERC
Portfolio after 10yr
$494.5K
Annual income
$125,210.78/yr
Blended yield
25.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CERC
Analyst Ratings
5
Buy
1
Hold
Consensus: Buy
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CERC buys
0
JNJ buys
0
No recent congressional trades found for CERC or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCERCJNJ
Forward yield68.26%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$968.9K$20.0K
Annual income after 10y$249,593.79$827.78
Total dividends collected$822.0K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CERC vs JNJ ($10,000, DRIP)

YearCERC PortfolioCERC Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$17,526$6,825.94$10,676$355.77+$6.8KCERC
2$29,933$11,180.47$11,407$389.39+$18.5KCERC
3$49,875$17,846.30$12,198$426.53+$37.7KCERC
4$81,156$27,790.26$13,056$467.62+$68.1KCERC
5$129,099$42,261.97$13,987$513.12+$115.1KCERC
6$200,966$62,830.03$14,998$563.56+$186.0KCERC
7$306,442$91,407.71$16,098$619.52+$290.3KCERC
8$458,156$130,263.77$17,295$681.69+$440.9KCERC
9$672,242$182,014.41$18,599$750.82+$653.6KCERC
10$968,892$249,593.79$20,022$827.78+$948.9KCERC

CERC vs JNJ: Complete Analysis 2026

CERCStock

Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.

Full CERC Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this CERC vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CERC vs SCHDCERC vs JEPICERC vs OCERC vs KOCERC vs MAINCERC vs ABBVCERC vs MRKCERC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.